Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2018-07-27 Capital/Financing Update
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
FORM S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is a registration statement used for securities offerings under the Securities Act of 1933. It includes detailed information about the securities to be registered, selling stockholders, and terms of the offering. This type of filing is related to capital raising activities and financing transactions. It is not an annual report, earnings release, or any other type of financial or governance report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual registration statement, not just an announcement or a brief notice.
2018-07-27 English
PRIMARY DOCUMENT
Director's Dealing
2018-06-26 English
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Galectin Therapeutics Inc. It is a registration statement under the Securities Act of 1933 for registering shares to be issued under an incentive compensation plan. The document includes legal and regulatory disclosures, incorporation by reference of prior filings, and indemnification provisions for directors and officers. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration and compliance, not a report or announcement of financial results or corporate governance changes. Therefore, it fits best under the category of Regulatory Filings (RNS).
2018-06-26 English
PRIMARY DOCUMENT
Director's Dealing
2018-06-21 English
Director's Dealing 2018
Director's Dealing
2018-06-20 English
Director's Dealing 2018
Director's Dealing
2018-06-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.